Term
|
Definition
| no enzyme activity; affects proton pump inhibitors |
|
|
Term
|
Definition
| no enzyme activity; affects SSRIs, tamoxifen, codeine, beta-blockers |
|
|
Term
|
Definition
| ultra rapid metabolizer; affects SSRIs, tamoxifen, codeine, beta-blockers |
|
|
Term
|
Definition
| high risk of abacavir-induced hypersensitivity reaction |
|
|
Term
|
Definition
| reduced enzyme activity (60-70% activity); affects Warfarin |
|
|
Term
|
Definition
| reduced enzyme activity (5% activity); affects Warfarin |
|
|
Term
|
Definition
| less enzyme activity; affects Warfarin |
|
|
Term
|
Definition
| associated with inter-individual variability in warfarin dose requirements (no testing available) |
|
|
Term
|
Definition
| results in aminoacid change 174/Val/Ala; reduces OAT1B1 transport activity; associated with increased statin concentrations thus increasing the risk for myopathy |
|
|
Term
|
Definition
| associated with increased risk of CHD; cannot transport statins intra-cellularly along microtubules |
|
|
Term
|
Definition
| reduced enzyme activity; affects Irinotecan (Camptosar) -- also decreased glucuronidation results in bilirubin buildup (--> jaundice!) |
|
|
Term
|
Definition
| activation of downstream signaling pathways and confers resistance to inhibition of cell surface receptor tyrosine kinases such as EGFR; affects Cetuximab and Panitumumab |
|
|
Term
|
Definition
| decreased enzyme activity; affects Tamoxifen (and SSRIs, Codeine, beta-blockers) |
|
|
Term
|
Definition
| no enzyme activity; affects Tamoxifen (and SSRIs, Codeine, beta-blockers) |
|
|
Term
|
Definition
| increased enzyme activity; affects Tamoxifen (and SSRIs, Codeine, beta-blockers) |
|
|
Term
|
Definition
| causes deficiency leading to decreased clearance of the inactive methylated metabolites and greater toxicity including myelosuppression and hepatotoxicity; affects Mercaptopurine |
|
|
Term
|
Definition
| increased endoxifen levels (active metabolite of tamoxifen), so that endoxifen isn't glucuronidated and excreted |
|
|
Term
|
Definition
| deletion of this gene affects the glucuronidation pathway for exemestane |
|
|
